You just read:

AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C

News provided by

AbbVie

14 Mar, 2017, 08:00 ET